TIPRANAVIR in English translation

• tipranavir

Examples of using Tipranavir in Croatian and their translations into English

Ukupne koncentracije tipranavira u plazmi za ove uzorke varirale su od 9 do 82 M.
Total plasma tipranavir concentrations for these samples ranged from 9 to 82M.

Apsorpcija tipranavira u ljudi je ograničena,
Absorption of tipranavir in humans is limited,

Istodobna primjena tipranavira i vitamina E nije ispitivana na psima.
Co-administration of tipranavir and vitamin E has not been studied in dogs.

Iskustvo s predoziranjem tipranavirom u ljudi je vrlo ograničeno.
Human experience with tipranavir overdose is very limited.

Smanjenje koncentracija tipranavira može rezultirati smanjenom djelotvornošću.
The decrease in tipranavir concentrations may result in decreased effectiveness.

Farmakokinetika tipranavira nije ispitivana u bolesnika s oštećenjem bubrega.
Tipranavir pharmacokinetics have not been studied in patients with renal impairment.

Ne postoji poznati antidot za predoziranje tipranavirom.
There is no known antidote for tipranavir overdose.

Jedan bolesnik na tipranaviru je imao četiri mutacije.
One patient in the tipranavir arm had four mutations.

Profil interakcija tipranavira s niskom dozom ritonavira je složen.
The interaction profile of tipranavir, co-administered with low dose ritonavir, is complex.

Uz ponavljano doziranje, koncentracije tipranavira u plazmi su niže od predviđenih iz podataka za jednokratnu dozu,
With repeated dosing, tipranavir plasma concentrations are lower than predicted from single dose data,

Toksikološka ispitivanja na životinjama izvođena su s monoterapijom tipranavirom na miševima, štakorima
Animal toxicology studies have been conducted with tipranavir alone, in mice,

istodobna primjena tipranavira s niskom dozom ritonavira
co-administration of tipranavir with low dose ritonavir

S tipranavirom i niskom dozom ritonavira zbog inhibicije CYP3A i P-gp tipranavirom/ritonavirom.
Colchicine concentrations may increase upon co-administration with tipranavir and low dose ritonavir, due to tipranavir/ritonavir CYP3A and P-gp inhibition.

Neispravna provedba istodobne primjene tipranavira s ritonavirom rezultirat će sniženim razinama tipranavira u plazmi koje mogu biti nedostatne za postizanje željenog antivirusnog učinka.
Failure to correctly co-administer tipranavir with ritonavir will result in reduced plasma levels of tipranavir that may be insufficient to achieve the desired antiviral effect.

Ispitivanja istodobne primjene tipranavira i ritonavira nisu otkrila dodatne toksikološke učinke u usporedbi s monoterapijom tipranavirom.
Studies with co-administration of tipranavir and ritonavir did not reveal any additional toxicological effects when compared to those seen in the tipranavir single agent toxicological studies.

Tijekom 12-satnog intervala, AUC tipranavira iznosio je 851 ± 309 µM•h(CL=1, 15 l/h) u žena i 710 ± 207 µM•h(CL=1, 27 l/h) u muškaraca.
Tipranavir AUC over a 12 hour dosing interval averaged 851± 309 µM•h(CL=1.15 l/h) for female patients and 710± 207 µM•h(CL=1.27 l/h) for male patients.

U kliničkim ispitivanjima veći porast lipida u krvi je primijećen kod liječenja sa tipranavirom/ritonavirom, nego kod liječenja s komparatorima drugim inhibitorima proteaze.
A higher increase of blood lipids were seen with tipranavir/ritonavir than with comparators(other protease inhibitors) in clinical trials.

Ne očekuje se da povećanje želučanog pH, koje može biti rezultat terapije antagonistomH2- receptora, utječe na koncentracije tipranavira u plazmi.
An increase in gastric pH that may result from H2-receptor antagonist therapy is not expected to have an impact on tipranavir plasma concentrations.

Trenutno ne postoje rezultati iz kontroliranih ispitivanja o učinku tipranavira na kliničku progresiju HIV infekcije.
At present there are no results from controlled trials evaluating the effect of tipranavir on clinical progression of HIV.

koncentracije bosentana se mogu povećati nakon istodobne primjene s tipranavirom uz nisku dozu ritonavira.
bosentan concentrations may increase upon co-administration with tipranavir and low dose ritonavir.